Biotech Startups

MyForest Foods produces farm-grown mycelium as a new whole-food category, developing plant-based food products aimed at consumers seeking nutritious and environmentally friendly options. The company operates in the alternative protein and foodtech space.

4 investors

MyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.

4 investors

Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment. The company focuses on discovering novel payloads to address unmet oncology needs.

4 investors

Nanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients. The company builds on French scientific research and targets patients worldwide through disruptive treatment approaches.

4 investors

Nanoligent is a biotech spin-off of the Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau that uses protein engineering and nanobiotechnology to develop targeted drug therapies, with a first cancer candidate targeting the CXCR4 receptor to limit tumor growth and metastasis. Its technology produces protein conjugates organized as nanoparticles for site-specific drug delivery aimed at oncology and potentially other disease biomarkers.

4 investors

Nanomik develops microencapsulation ("Microsome") technology and biological active substances of botanical and microbial origin for fungicidal and insecticidal agricultural products used in crop protection and plant nutrition. The company serves the food and agriculture sector, handling R&D, field trials, formulation, production, and regulatory registration of its products.

4 investors

NanoString (part of Bruker Spatial Biology) develops instruments and assays for spatial biology and gene expression analysis, including single-cell and subcellular spatial transcriptomics, proteomics, and multiomics. Its systems serve researchers in oncology, biomarker discovery, neuroscience, and translational and clinical research.

4 investors

Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.

4 investors

Nebula Genomics offers whole genome sequencing, providing consumers with health, trait, ancestry, and oral microbiome reports based on 100% of their DNA. Its DNA Complete product delivers 350+ personalized genetic reports across categories such as cardiovascular health, brain health, and wellness.

4 investors

Neion Bio operates a biomanufacturing platform that re-engineers eggs into living bioreactors using genetic engineering and stem cell biology to produce biological molecules such as monoclonal antibodies, enzymes, fusion proteins, peptides, and cytokines. It serves biopharma partners across biosimilars, biotech, animal health, and reagents, aiming to lower the cost and improve the consistency of biologics manufacturing.

4 investors

Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.

4 investors

Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy. It also maintains a proprietary drug delivery and stabilization technology portfolio applicable to proteins, peptides, and small and large molecules.

4 investors

Neurovalens develops medical devices using neuromodulation technology to address health conditions including obesity and anxiety disorders. The company conducts research and development activities supported by European funding programs.

4 investors

NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions. The company aims to provide lipid-lowering treatments that help patients with cardiovascular risk manage their health.

4 investors

Newform Foods is a South African food technology company focused on food and biotech research, including cultivated meat and agri-innovation. It has launched the Newform Applied Biotech Centre at South Ormsby Estate in Lincolnshire, UK.

4 investors

NewLeaf develops PPFM (Pink-Pigmented Facultative Methylotroph) microbial technologies for agriculture, offering EPA-registered biofungicide and bioinsecticide products (TS601 and TS201) plus crop-specific biostimulants for growers of corn, soy, cotton, rice and other crops. Its biological BioControl and biostimulant products aim to protect crops from pests and diseases and improve yield.</parameter> <parameter name="founders">[]

4 investors

NextBiomedical develops innovative polymer-based pharmaceutical and medical device technologies designed to overcome limitations of existing therapeutics. The company specializes in adhesive polymers, polysaccharides, and microparticle formulations for controlled drug delivery and enhanced biocompatibility.

4 investors

Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration. Its lead program is an antibody targeting the pathogenic form of alpha-synuclein in Parkinson's disease, with a pipeline aimed at neurodegenerative, cancer, fibrotic, respiratory, and autoimmune diseases.

4 investors

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.

4 investors

NK:IO develops natural killer (NK) cell and small molecule therapies for cancer, targeting both haematological and solid tumours such as ovarian cancer. Its platform technologies, based on umbilical cord blood stem cells, aim to expand NK cells and enhance their tumour-killing capacity for cancer immunotherapy, with programmes at the research and early preclinical stage.

4 investors

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs. The company works with patients, caregivers, and healthcare professionals throughout discovery and clinical development.

4 investors

Novadip develops regenerative medicine treatments using its 3M3 tissue regeneration platform to address conditions requiring bone and tissue repair, including spinal fusion, cancer recovery, and complex fractures.

4 investors

Novai applies advanced molecular and computational approaches to eye disease, supporting clinicians and researchers in translating scientific findings into patient treatment options.

4 investors

Nūmi uses cell culture technology to produce a new form of nutrition, aiming to replicate the benefits of breast milk as an alternative for parents and infants, with potential applications across other age groups. It operates in the food and biotech space focused on human nutrition and health.

4 investors